5 drug(s) with this reaction
5,278 total reports
Product Dose Omission Issue has been reported as an adverse reaction across 5 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,278 adverse event reports mention product dose omission issue in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with product dose omission issue, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have product dose omission issue listed in their FDA adverse event reports, sorted by report count:
In addition to product dose omission issue, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
5 drug(s) manufactured by Abbvie Inc have product dose omission issue listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, DIVALPROEX SODIUM, FENOFIBRATE, PANCRELIPASE, ATOGEPANT.
There are a combined 5,278 reports of product dose omission issue across 5 Abbvie Inc drug(s) in the FDA adverse event database.